Szatmary L J, Rabloczky G, Kurthy M, Varro A, Solti F
Institute for Drug Research, University Hospital, Semmelweis University Medical School, Budapest, Hungary.
Acta Med Hung. 1988;45(2):209-19.
Cardiac electrophysiological properties of GYKI-23107, a new membrane stabilizing antiarrhythmic agent were studied in anaesthetized open-chest dogs. Epi- end endocardial electrograms (for sinus potential and for His bundle recording) were obtained during sinus rhythm and following atrial and ventricular pacing. The registration were performed under control conditions as well as five minutes after drug administration of 8 mg/kg slow i.v. or 20 minutes after 20 mg/kg intraduodenal administration respectively. GYKI-23107 did not influence significantly either the sinus cycles, PA-intervals, sinus node potentials, or the classical electrophysiological parameters of sinoatrial function as the corrected recovery time of the sinus node, sino-atrial conduction time or the secondary post-stimulation sinus cycles before and after vegetative blockade. Neither the AH intervals, anterograde Wenckebach period, nor ventriculo-atrial conduction time changed significantly. QRS duration, configuration and HV-intervals remained also unchanged after drug administration in doses which used in this study, and which seemed to be in therapeutic range. The agent did not influence significantly the effective refractory periods of the atrium and ventricle during sinus rhythm. This study suggest that the GYKI-23107 is not depressive on the anterograde (AV), retrograde (VA), intraventricular conduction and is slightly depressive on the intrinsic pacemaker properties.
在麻醉开胸犬身上研究了新型膜稳定抗心律失常药物GYKI-23107的心脏电生理特性。在窦性心律期间以及心房和心室起搏后获取心外膜和心内膜心电图（用于记录窦性电位和希氏束）。记录分别在对照条件下以及静脉缓慢注射8mg/kg药物后5分钟或十二指肠给药20mg/kg后20分钟进行。GYKI-23107对窦性周期、PA间期、窦房结电位或窦房功能的经典电生理参数（如窦房结的校正恢复时间、窦房传导时间或自主神经阻断前后的二次刺激后窦性周期）均无显著影响。AH间期、前向文氏周期或室房传导时间也均无显著变化。在本研究中使用的且似乎处于治疗范围内的剂量给药后，QRS波时限、形态及HV间期也保持不变。该药物对窦性心律时心房和心室的有效不应期无显著影响。本研究表明，GYKI-23107对前向（房室）、逆向（室房）、室内传导无抑制作用，对固有起搏特性有轻微抑制作用。
